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Inflammation is a prominent feature of CNS injury
that heavily influences neuronal survival, yet the
signals that initiate and control it remain poorly
understood. Here we identify the nuclear alarmin,
interleukin (IL)-33, as an important regulator of
the innate immune response after CNS injury. IL-33
is expressed widely throughout the healthy brain
and is concentrated in white mater due to predomi-
nant expression in post-mitotic oligodendrocytes.
IL-33 is released immediately after CNS injury
from damaged oligodendrocytes, acting on local
astrocytes and microglia to induce chemokines crit-
ical for monocyte recruitment. Mice lacking IL-33
have impaired recovery after CNS injury, which
is associated with reduced myeloid cell infiltrates
and decreased induction of M2 genes at the injury
site. These results demonstrate a novel molecular
mediator contributing to immune cell recruitment
to the injured CNS and may lead to new thera-
peutic insights in CNS injury and neurodegenerative
diseases.
INTRODUCTION
CNS injury is devastating for those afflicted, frequently resulting
in permanent impairment due to limited prospects for normal
regeneration. Neurons and glia directly damaged by the initial
insult die, both necrotically and apoptotically (Grossman et al.,
2001; Liu et al., 1997; Lytle andWrathall, 2007), followed by sec-
ondary degeneration—a spread of damage through apoptotic
death of initially uninjured neurons (Dusart and Schwab, 1994).
The immune system detects and rapidly responds to injury
with a cascade of peripheral effectors and soluble molecules
(Trivedi et al., 2006). The overall impact of this immune response
remains debated, as it has potential to drive both beneficial
(Shechter et al., 2013; Walsh et al., 2015; Walsh et al., 2014)and detrimental (Evans et al., 2014; Kroner et al., 2014) effects
on recovery. A potential explanation of these dual aspects is
macrophage phenotype, with the alternative (M2) and classical
(M1) polarization correlating with beneficial or detrimental re-
sponses, respectively (Kigerl et al., 2009; Kroner et al., 2014;
Schmitz et al., 2005; Shechter et al., 2009, 2013).
Interleukin (IL)-33 is a nuclear alarmin of the IL-1 cytokine fam-
ily released by cell damage and is well characterized as an
immune activator in conditions such as asthma (Liew et al.,
2010), allergy (Oboki et al., 2010), and sepsis (Alves-Filho
et al., 2010). Upon release from necrotically dying cells (Lu¨thi
et al., 2009), IL-33 binds IL-33R, a heterodimer of IL-1RAcP
and ST2, and initiates an intracellular cascade involving MyD88
and NFkB (Liew et al., 2010). In addition to barrier tissues such
as lung and skin, IL-33 is highly expressed in the CNS (Schmitz
et al., 2005), though its endogenous location and function
remains understudied there. Astrocytes have been suggested
as the cellular source of IL-33 (Yasuoka et al., 2011), but this
remains poorly characterized in vivo. Furthermore, the cellular
targets within the CNS and the potential role of expressed IL-
33 in regulating the immune response following trauma remains
unknown.
Here we provide evidence that in the healthy brain IL-33 is ex-
pressed mainly by post-mitotic oligodendrocytes and gray mat-
ter astrocytes. It is released immediately after CNS injury and
acts upon astrocytes (and microglia) to induce production of
chemokines critical for monocyte recruitment. IL-33 also acts
on monocytes to augment their M2 skew, previously shown to
be beneficial after CNS injury. Lack of IL-33 results in diminished
numbers of infiltrating neuroprotective M2-skewed macro-
phages and, therefore, leads to impaired recovery after CNS
injury.
RESULTS
We first examined the expression levels of IL-33 in different re-
gions of the healthy periphery and CNS. There is high variability
of IL-33 expression among CNS areas, with a trend toward tis-
sues with higher myelin content exhibiting higher IL-33 expres-
sion (Figure 1A; Figure S1A). Given the high expression levelsNeuron 85, 703–709, February 18, 2015 ª2015 Elsevier Inc. 703
Figure 1. IL-33 Is Highly Expressed in
Myelinated Tissue due to Enrichment in
Oligodendrocytes
(A) Mouse peripheral tissues and brain regions
were isolated and analyzed for IL-33 transcript (n =
3; one-way ANOVA with Tukey’s multiple com-
parison test). (B) Representative labeling of OLIG2
and IL-33 in spinal cord gray matter of (top) WT
mice (white arrows = OLIG2+ IL-33+ cells; yellow
arrows = OLIG2+ IL33– cells) and (bottom) IL-33–/–
mice as a negative control. (C) Representative la-
beling of CC-1 and IL-33 in WT spinal cord gray
matter (white arrows = CC-1+ IL-33+ cells; yellow
arrows =CC-1+ IL33– cells; blue arrows =CC-1– IL-
33+ cells). (D) Quantification of IL-33-, OLIG2-, and
CC-1-positive cells in multiple CNS regions (data
are presented as mean counts from four to five
individual animals). (E) Representative image of
OLIG2 and IL-33 labeling in neocortex (white ar-
rows = OLIG2+ IL-33+ cells; yellow arrows =
OLIG2+ IL33– cells; blue arrows = OLIG2– IL-33+
cells). (F) Representative labeling of IL-33 and
ALDH1L1 in the neocortex (white arrows =
ALDH1L1+ IL-33+ cells; yellow arrows = ALDH1L1–
IL33+ cells). (G) Quantification of ALDH1L1 and
IL-33 labeling in multiple CNS regions (data are
presented as mean counts from four to five indi-
vidual animals). (H) Representative gating strategy
for isolating oligodendrocyte lineage cells from
whole brain by flow cytometry. Gates for oligo-
dendrocyte antigens were drawn based on fluo-
rescence minus one (FMO) controls, gates for
IL-33 were drawn based on IL-33–/– samples. (I)
Histograms showing IL-33 expression in several
CNS cell populations isolated from whole brain for
flow cytometry. Black lines represent staining of
IL-33–/– brain. (J and K) Summary of MFI of IL-33+
populations (J) and percent of cells expressing
IL-33 (K) (n = 3–4; one-way ANOVA with Tukey’s
multiple comparison test). Error bars represent
mean ± SEM; *p% 0.05; **p% 0.01; ***p% 0.001.of IL-33 in myelinated areas, we suspected oligodendrocytes to
be a primary CNS source for IL-33. To test this, we performed
immunofluorescent labeling for IL-33 and OLIG2, a transcription
factor expressed mainly by cells of the oligodendrocyte lineage.
There is substantial colocalization of these markers, revealing
enriched IL-33 expression in OLIG2+ cells in several CNS regions
(Figure 1B; Figure S1B). To identify mature oligodendrocytes, we
co-labeled IL-33 with CC-1 (APC), again demonstrating a high
degree of co-expression (Figure 1C). In most tissues analyzed,704 Neuron 85, 703–709, February 18, 2015 ª2015 Elsevier Inc.the majority of IL-33-positive cells were
mature oligodendrocytes (Olig2+CC-1+;
Figure 1D), but there was a significant
portion of non-oligodendrocyte IL-33+
cells in regions such as spinal cord gray
matter and neocortex (Figure 1E). Co-
staining of IL-33with the astrocytemarker
ALDH1L1 (Cahoy et al., 2008) demon-
strated that these cells were astrocytes,
which express IL-33 in gray matter re-gions (i.e., neocortex) but not in white matter (i.e., corpus cal-
losum; Figures 1F and 1G). To further describe the expression
of IL-33 in subsets of the oligodendrocyte lineage, we performed
flow cytometry of healthy whole brain (Figure 1H). About 33% of
isolated brain cells were IL-33+ (Figure 1I). IL-33 expression
increased in oligodendrocytes with maturity and myelination:
myelinating oligodendrocytes (OLIG2+ MOG+) express the
most IL-33 both as a percent of cells and by mean fluorescent
intensity (MFI), whereas pre-myelinating oligodendrocytes and
Figure 2. IL-33 Is Released after CNS Injury
without Induction of New Transcript
(A) Representative image of a spinal cord injury
site 1DPI stained for IL-33. IL-33-positive nuclei
are present adjacent to the injury (top right) but
absent at the injury site (bottom right). Images are
representative of four individual animals. (B) CSF
was gathered from mice after spinal cord contu-
sion and analyzed for IL-33 by ELISA. IL-33 was
detectable only at 1 hr post-injury (n = 3 mice per
group). (C) IL-33 ELISA of in vitro contused spinal
cords. 4 mm pieces of spinal cord were contused
in individual wells of a 96-well plate and incubated
for 10 min, 1 hr, or 30 hr before supernatants
were collected for ELISA (n = 5 individual animals;
one-way ANOVA with Tukey’s multiple compari-
son test). (D) Spinal cord segments release
more IL-33 with contusion than without (n = 5
individual animals; paired two-tailed t test). (E)
In vitro contused spinal cords were harvested and
analyzed for IL-33 transcript, showing no induction
of IL-33 mRNA (n = 5 mice per group; one-way
ANOVA with Tukey’s multiple comparisons test).
Error bars represent mean ± SEM; *p % 0.05;
**p% 0.01; ***p% 0.001.oligodendrocyte precursor cells (OPCs) express significantly
less (Figures 1J and 1K). IL-33 expression was minimal to none
in neurons, microglia, or proliferating Ki-67+ cells (Figures
S1C–S1E). We conclude that in the healthy CNS, IL-33 is ex-
pressed by the majority of post-mitotic oligodendrocytes and
by gray matter astrocytes.
We next sought to test whether IL-33 in the CNS acts as alar-
min. Immunofluorescence analysis of the injured spinal cord
1 day post-injury (1DPI) demonstrates a disappearance of IL-
33 from the lesion site (Figure 2A), suggesting its release from
damaged tissue. To further assess the kinetics of release, we
measured IL-33 in the cerebrospinal fluid (CSF) after spinal
cord injury. IL-33 is not detectable in healthy CSF, but it appears
1 hr after spinal cord contusion. IL-33 presence is transient, not
being detectable at 3 or 24 hr post-injury (Figure 2B), likely due to
rapid CSF recirculation. Spinal cord segments contused in vitro
released IL-33 within 10 min, with maximum release at 1 hr that
persisted after 30 hr in the supernatant (Figure 2C). Uncontused
spinal cords also released IL-33 due to the injury of excision
itself, albeit at a lower concentration (Figure 2D). Notably,
in vitro release of IL-33 protein occurred without induction of
new transcription (Figure 2E). These data suggest release of
endogenously expressed protein after injury instead of its de
novo synthesis.
To address the role of IL-33 in recovery from CNS trauma, we
subjected IL-33–/– and wild-type (WT) mice to an optic nerve
crush injury (Yoles and Schwartz, 1998), a model that is depen-
dent on immune assistance for optimal neuronal survival (Kipnis
et al., 2004; Walsh et al., 2015). In this assay, retinal ganglion
cells (RGCs) are pre-labeled with the retrograde tracer Fluoro-Gold (FG) injected stereotaxically into the superior colliculus. A
compression injury is inflicted to the optic nerve 3 days post la-
beling, and retinal ganglion cell (RGC) survival is assessed 7 days
after the injury by counting labeled RGCs on whole-mounted
retinas (Figure 3A). IL-33–/– mice showed significantly less RGC
survival after optic nerve injury as revealed by FG labeled cell
enumeration (Figure 3B). RGCs are distributed unevenly across
themouse retina, becoming less dense further away from the op-
tic disk (Ortı´n-Martı´nez et al., 2014). The images were taken at
points equidistant to the optic disk, but to further confirm that
no difference in RGC distribution exist inWT and IL-33–/– animals
with and without injury, we quantified RGC number at adjacent
fields moving distal to the optic disk (Figures S2A–S2C).
To assess whether IL-33-expressing cells must be actually
damaged for IL-33 to have an effect, we used a second retinal
injury model, intraocular glutamate injection (Schori et al.,
2002). IL-33 is abundant in the optic nerve but is not highly ex-
pressed in the retina. Seven days after glutamate injection, we
counted RGCs by labeling them using their specific transcription
factor Brn3a (Figure 3C). As expected, direct glutamate toxicity
did not lead to exaggerated retinal ganglion cell death in IL-
33–/– mice compared to their WT controls (Figure 3D).
Optic nerve injury is a model of severe CNS damage. The ma-
jority of RGCs die inWTmice, making it challenging to sensitively
detect further impairment due to a floor effect (Levkovitch-Verbin
et al., 2000). To repeat our findings in another model with a func-
tional readout, we tested recovery of IL-33–/– mice after spinal
cord contusion injury (SCI). Consistent with the high expression
of IL-33 in the spinal cord and in line with our findings in optic
nerve injury, IL-33–/– mice had significantly impaired recoveryNeuron 85, 703–709, February 18, 2015 ª2015 Elsevier Inc. 705
Figure 3. IL-33 Is Beneficial after CNS Injury
and IL-33–/– Have Decreased M2 Macro-
phage Activity at the Injury Site
(A) Representative images of Fluorogold-labeled
RGCs with and without optic nerve crush in WT
and IL-33–/–. (B) Quantification of RGC survival in
WT and IL-33–/– animals (n = 9–11; two-tailed
Student’s t test). (C) Representative images of
Brn3a-labeled RGCs with and without glutamate
treatment. (D) Quantification of RGC survival after
glutamate toxicity (n = 5; two-tailed Student’s
t test). (E) Recovery after spinal cord contusion
(90 KDyn) as measured by the BassoMouse Scale
(BMS) (Basso et al., 2006) (n = 8 mice per group,
representative of 3 experiments with 70–90 KDyn
severity; repeated-measures two-way ANOVA
with Sidak’s multiple comparisons test). Motor
coordination was assessed with the (F) Rotarod
and (G) Pole tests. (F) After two training trials, WT
and IL-33–/– mice were placed on an accelerating
rod and the latency to fall was recorded (n = 7–10;
two-tailed Student’s t test). (G) After one training
trial, mice were placed at the top of a narrow pole
and latency to descend the pole was recorded (n =
9; two-tailed Student’s t test). (H) Representative
injury sites of WT and IL-33–/– animals 14 days
after spinal cord contusion labeled with GFAP and
IBA1. (I) Volume of lesion sites at 23DPI as
measured by GFAP delineation. (J) 1 cm of spinal
cord tissue centered on the 1DPI lesion site was
analyzed for transcript levels of M2 genes in WT
and IL-33–/– animals (n = 3, representative of two
experiments; multiple two-tailed Student’s t tests).
(K) BMDMs were treated with IL-4 (10 ng/ml), anti-
ST2 antibodies (10 ng/ml) and dissected 2.5 mm
segments of mouse spinal cord for 24 hr in vitro
before lysates were analyzed for Arginase 1
transcript (n = 3; (main graph) one-way ANOVA
with Tukey’s multiple comparisons test; (inset)
two-tailed Student’s t test). (L) BMDMs were
treated with IL-4 (10 ng/ml), anti-ST2 antibodies
(10 ng/ml), and optic nerves from WT or IL-33–/–
animals (1 optic nerve/well of a 24-well plate, cut
into 2 pieces) for 24 hr and analyzed for Arg1
transcript (n = 3, representative of 2 experiments;
(main graph) one-way ANOVA with Tukey’s
multiple comparisons test; (inset) two-tailed
Student’s t test). (M and N) WT or ST2–/– BMDMs
were treated with IL-4 (10 ng/ml), IFNg (100 ng/ml), or optic nerves (as in B), for 24 hr and analyzed for Arg1 or Nos2 transcript (n = 3, representative of two
experiments; two-way ANOVA with Sidak’s multiple comparisons test). Error bars represent mean ± SEM; *p% 0.05; **p% 0.01; ***p% 0.001.relative to WT counterparts after SCI, as assessed by Basso
mouse scale (Basso et al., 2006) (Figure 3E). Notably, uninjured
IL-33–/– mice showed no deficits in the rotarod (Figure 3F) and
pole (Figure 3G) tests, suggesting that IL-33 deficiency does
not affect baseline motor function in these tasks.
To analyze the volume of the site of injury, we immunolabeled
injured spinal cords with GFAP (reactive astrocytes) and IBA1
(myeloid cells; Figure 3H). Quantification of the lesion volume
based on GFAP delineation in coronal sections revealed
significantly increased lesion size in IL-33–/– versus WT animals
(Figure 3I).
Given previous reports showing that IL-33 can polarize toward
an ‘‘M2’’ (IL-4-activated) macrophage skew (Kurowska-Stolar-706 Neuron 85, 703–709, February 18, 2015 ª2015 Elsevier Inc.ska et al., 2009) and that M2 macrophages promote neuronal
survival (Kigerl et al., 2009), we analyzed the lesion site for
expression of several characteristic M2 markers. Indeed, there
were significant decreases in expression of several M2-associ-
ated genes, but the M1-associated gene Nos2 was unchanged
(Figure 3J). To better understand how IL-33 from injured CNS tis-
sue drives macrophage phenotype, we established an in vitro
system where bone marrow-derived macrophages (BMDMs)
are polarized with IL-4 in the presence of acutely excised healthy
CNS tissue (2.5 mm of spinal cord or 1 optic nerve per well). WT
BMDMs treated with IL-4 display an expected increase of Arg1,
which is substantially intensified by co-incubation with injured
spinal cord (Figure 3K). Of note, spinal cord alone has little effect
on Arg1, suggesting that the tissue emits one (or several) alar-
mins that potentiates rather than directs the macrophage M2
phenotype. Adding an antagonizing antibody to ST2 dampened
the amplifying effect of spinal cord tissue (Figure 3K). We next
testedwhether optic nerves also potentiate M2 skew. Incubating
macrophages with IL-4 and excised optic nerves yielded a
similar enhancement of Arg1, again attenuated by anti-ST2 anti-
bodies (Figure 3L). Moreover, optic nerves from an IL-33–/– mice
potentiated M2 skew to a significantly less extent than WT optic
nerves (Figure 3L). We repeated these experiments using
BMDMs from ST2–/– donors and, as expected, potentiation of
their M2 skew by injured optic nerves was significantly lower
than in WT macrophages (Figure 3M). Additional M2-associated
genes were altered (Figure S3A). Conversely, injured optic nerve
in combination with IFNg did not potentiate M1 skew of macro-
phages as measured byNos2 (Figure 3N), suggesting IL-33 spe-
cifically boosts aspects of the M2 response. Importantly, no
manipulation to IL-33 signaling alone completely abrogated the
potentiating effect of CNS tissue on Arg1 expression, and IL-
33 had little effect on some M2 genes such as Mrc, suggesting
that IL-33 is likely one of several alarmins potentiating the M2
phenotype.
We next assayed M2-associated gene expression on isolated
CD11b+ cells from the 1DPI injury site, and surprisingly saw no
difference in expression of several M2 genes (Figure S3B). Given
these findings, we hypothesized that our prior observation of
reducedM2 gene expression in thewhole IL-33–/– lesion site rep-
resented a reduction in the overall number of M2 cells relative to
other brain cells rather than an impaired M2 polarization.
We assessed the number of peripheral myeloid cells entering
the injured spinal cord by flow cytometry. Gating on live/nucle-
ated/CD45hi (excluding CD45lo microglia)/CD11b+ cells, we
quantified numbers of infiltrating monocytes and granulocytes
at the site of injury (Figure 4A). At 1DPI, therewas a striking reduc-
tion in the number of Ly6Chi monocytes in the IL-33–/– spinal
cords (Figures 4B and 4C). The early lack of monocyte recruit-
ment continued to affect later immune cell composition, with
reduced Ly6cloF4/80+ monocyte-derived macrophages at 7DPI
(Figures 4D and 4E). It has previously been reported that the
majority of Arg1+ cells entering the CNS injury site are infiltrating
monocytes (Hsieh et al., 2013), and we confirmed by immuno-
fluorescent analysis of the 1DPI injury site that there are fewer
Arg1+ cells in IL-33–/– animals relative to WT (Figures 4F and 4G).
Previous studies have shown that cultured glia produce the
chemokine CCL2 (MCP1) in response to IL-33 stimulation (Kem-
puraj et al., 2013). We sought to explore other chemokines
that could be induced with IL-33 stimulation. Luminex of IL-33-
treated mixed glial culture supernatants revealed in addition to
CCL2, significant secretion of CXCL1 (KC), CXCL2 (MIP2-a),
CXCL10 (IP-10), and CCL5 (RANTES) (Figure 4H). Looking at
chemokine induction at the injury site 1DPI, we observed reduc-
tions in several of these chemokine transcript levels in IL-33–/–
mice;Ccl2,Cxcl10, andCxcl2 are reduced at the injury site, while
Ccl5 and Cxcl1 are unchanged (Figure 4I).
Mixed glia cultures contain several potential cellular targets
for IL-33, and to narrow the specific cell responding to IL-33
with chemokine production, we screened different populations
of glia after IL-33 stimulation. We sorted CD11b+ microglia outfrom a mixed glia culture, resulting in a concentrated population
of astrocytes (the CD11b– fraction; 70% astrocytes and >95%
pure from microglia) (Figure S4A). We next added IL-33 to these
cultures and analyzed changes in gene expression by microar-
ray. This screen revealed that, while both fractions respond,
CD11b– glia are substantial producers of chemokines compared
to microglia (CD11b+ enriched cells) after IL-33 treatment (Fig-
ure S4B). Further RT-PCR analysis reinforced this, demon-
strating that IL-33 treatment results in strong induction of
monocyte-attracting chemokines such as CCL2 (Figure 4Ji)
and CXCL10 (Figure 4Jii) in CD11b– glia. Enriched microglia
cultures treated with IL-33 did not exhibit such induction of che-
mokines (Figure 4J).
This result compelled us to test the ability of CD11b– glia to
respond to IL-33 in vivo. Agreeing with previous literature, at
baseline microglia express the highest amounts of St2, while
other glia are lower expressers. Interestingly, however, after injury
St2 expression levels flip, with the CD11b+ fraction downregulat-
ingSt2 and theCD11b– fraction upregulatingSt2, arguing in favor
of CD11b– glia as post-injury IL-33 responders (Figure 4K).
To reaffirm the critical role of monocyte recruitment in contrib-
uting to impairment in IL-33–/– mice, we sought to enhance
recruitment by delivering CCL2, a major chemokine for recruit-
ment of peripheral monocytes into tissues including the CNS
(Ma et al., 2002). We titrated the dose of CCL2 administration,
seeing a dose-dependent increase in Ly6Chi monocyte recruit-
ment at 1DPI in WT mice (Figures S4C and S4D). Local adminis-
tration of 10 ng of CCL2 in IL-33–/– mice significantly improved
recovery in spinal cord-injured IL-33–/– animals (Figure 4L),
strengthening our conclusion that IL-33 is a critical factor for pro-
tective myeloid cell recruitment after injury.
DISCUSSION
It has long been recognized that CNS injury results in a vigorous
immune response, with rapid activation of microglia and astro-
cytes and recruitment of peripheral cells to the site of injury (Triv-
edi et al., 2006), but the signals that initiate inflammation remain
poorly understood. Here we further our understanding of the
alarmin IL-33 in the CNS. We show that IL-33 is expressed in
mature oligodendrocytes and gray matter astrocytes in the
healthy CNS and that it is released upon injury to promote mono-
cyte recruitment and recovery.
CNS-derived IL-33amplifiesmacrophagealternativeactivation
in vitro, and IL-33–/– mice have decreased expression of many
M2-associated genes at the injury site. Interestingly, isolated
CD11b+ cells from the injury site of IL-33–/– animals, albeit sub-
stantially fewer in numbers, have normal expression ofM2 genes.
Given the evidence that IL-33 works in concert with yet-uniden-
tified factors to drive skew in vitro, we predict that the skewing
effects of IL-33 in vivo are compensated for by other factors in
the IL-33–/– lesion site and that the effects of IL-33 we observed
in vitro may be relevant to other less dramatic CNS insults.
This study is an early foray into the biology of IL-33 in CNS
injury, focusing on how selectively removing IL-33 affects injury
outcome. Other studies have alluded to the importance of
IL-33 in other CNS pathologies: IL-33 treatment mitigates pa-
thology of EAE (Jiang et al., 2012) and human Alzheimer’sNeuron 85, 703–709, February 18, 2015 ª2015 Elsevier Inc. 707
Figure 4. IL-33–/– Mice Have Impaired
Myeloid Cell Recruitment and Chemokine
Induction after CNS Injury
(A) Example of gating for peripheral myeloid cells
at the injury site. Cells were gated as follows:
Hoescht+, CD45+, Singlets, live cells, CD11b+,
CD45hi. (B–E) Flow cytometry analysis of the injury
site 1 and 7 days after spinal cord injury. (B)
Representative plots of WT and IL-33–/– sites at
1DPI. (C) Mean cell numbers at the injury site of
total peripheral myeloid cells (CD11b+/CD45hi)
and subsets of monocytes (Ly6Chi/Ly6Glo), gran-
ulocytes (Ly6Cint/Ly6G+), and macrophages (Ly6-
Clo/Ly6Glo) (n = 3mice per group, representative of
two experiments; two-way ANOVA with Sidak’s
multiple comparison’s test). (D) Representative
flow plots and (E) summarized results comparing
WT and IL-33–/– injury sites at 7DPI. (n = 3mice per
group; two-way ANOVA with Sidak’s multiple
comparisons test). (F) Representative images of
Arg1+ cells at the lesion site 1DPI. (G) 1DPIWT and
IL-33–/– injury sites were analyzed by immunoflu-
orescence for Arg1+ cell number. Spinal cords
were sliced longitudinally and collected at equiv-
alent intervals in all mice, and at least seven
equivalent slices were analyzed per mouse. (n = 3;
two-tailed Student’s t test). (H) Luminex chemo-
kine analysis of mixed glial cultures after treatment
with IL-33 (100 ng/ml) for 24 hr. Data are shown as
fold induction relative to untreated cultures (n = 4;
multiple two-tailed Student’s t test). (I) Chemokine
transcript levels from the injury site at 1DPI in WT
versus IL-33–/– mice (n = 3 mice per group,
representative of two experiments; multiple two-
tailed Student’s t test). (J) qRT-PCR analysis of
chemokine induction from sorted CD11b+ and
CD11b– mixed glial culture populations treated
with IL-33 (100 ng/ml) overnight. Data are shown
as fold induction of (Ji)Ccl2 and (Jii)Cxcl10 relative
to untreated (n = 3; one-way ANOVA with Tukey’s
multiple comparisons test). (K) qRT-PCR analysis
of ST2 transcript levels from CD11b+ and CD11b–
sorted from the injury site (n = 3; two-way ANOVA
with Sidak’s multiple comparisons test). (L) CCL2
treatment (10 ng/mouse) rescues recovery deficits
in IL-33–/– animals (90 KDyn) (n = 5–6; repeated-
measures two-way ANOVA). Error bars represent
mean ± SEM; *p% 0.05; **p% 0.01; ***p% 0.001).disease is correlated with decreased CNS IL-33 expression
(Chapuis et al., 2009). IL-33 likely represents just one of many
alarmins originating from the injured or damaged CNS to recruit,
skew, and activate the immune response to CNS insults.
EXPERIMENTAL PROCEDURES
Mice
IL-33–/– mice were generated by the trans-NIH Knock-Out Mouse Project
(KOMP) and obtained from the KOMP repository (http://www.komp.org).
ST2–/– mice were generated in the lab of Dr. A. McKenzie (University of
Cambridge) and were gift from Dr. P. Bryce (Northwestern University). C57/
Bl6 and CX3CR1-eGFP mice were obtained from Jackson Laboratory, stocks
004999 and 005582, respectively. All animals were housed in temperature
and humidity controlled rooms, maintained on a 12 hr light/dark cycle (lights
on 7:00 a.m.), and age matched in each experiment. All strains were kept in708 Neuron 85, 703–709, February 18, 2015 ª2015 Elsevier Inc.identical housing conditions. For survival surgeries, mice were anesthetized
with either 200 ml of Ketamine/Xylazine (1 ml KetamineHCl (1mg/ml), 1 ml of
2% Xylazine, 8 ml saline), or inhaled isoflurane. All procedures complied
with regulations of the Institutional Animal Care and Use Committee (ACUC)
at the University of Virginia.
Statistics
Statistical tests performed in Prism (Graphpad) software as described in
the text and figure legends. In all figures, error bars represent mean ± SEM;
*p% 0.05; **p% 0.01; ***p% 0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.neuron.2015.01.013.
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